Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Primary Purpose : Treatment
Allocation : Randomized
Interventional Model : Parallel Assignment
Masking : None (Open Label)
Primary outcome measures:
Progression-free Survival (PFS)
Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high). Future studies are warranted to validate these findings
The authors' conclusion was that Increasing age ( ≥ 65 years) did not adversely affect clinical outcomes or safety with afatinib versus methotrexate in second-line R/M Head & Neck squamous cell carcinoma (HNSCC)…